Cargando…

LB14. Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Subjects Aged 65 Years and Older

BACKGROUND: Older adults (≥65 years of age) remain at increased risk of influenza because they do not respond to standard dose influenza vaccines as well as younger adults. A high dose, inactivated trivalent influenza vaccine, IIV3-HD, containing four times the antigen content (60 µg hemagglutinin p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Lee-Jah, Meng, Ya, Janosczyk, Helene, Landolfi, Victoria, Talbot, H Keipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253668/ http://dx.doi.org/10.1093/ofid/ofy229.2188

Ejemplares similares

Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older
por: Greenberg, David P., et al.
Publicado: (2017)

1054 Immunogenicity And Safety of Quadrivalent Influenza Vaccine Administered Intradermally (ID) in Adults 18 through 64 Years of Age
por: Gorse, Geoffrey J., et al.
Publicado: (2014)

Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial
por: Sanchez, Leilani, et al.
Publicado: (2019)

1967. Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) When Co-administered with Other Vaccines in Healthy Adolescents
por: Hedrick, James, et al.
Publicado: (2018)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
por: Agarkhedkar, Sharad, et al.
Publicado: (2019)

1059 Expanded immunogenicity of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine in older adults
por: Diazgranados, Carlos, et al.
Publicado: (2014)

Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial
por: Langley, Joanne M., et al.
Publicado: (2015)

Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults
por: Assantachai, Prasert, et al.
Publicado: (2023)

Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study
por: Pepin, Stephanie, et al.
Publicado: (2016)

Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults
por: DiazGranados, Carlos A., et al.
Publicado: (2016)

A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes
por: Slingluff, Craig L, et al.
Publicado: (2014)

160. Safety and Immunogenicity of Escalating Dose Formulations of High-dose Quadrivalent Influenza Vaccine in Children 6 Months Through < 18 Years of Age
por: Chang, Leejah, et al.
Publicado: (2020)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

2462. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Individuals 56 Years of Age and Older
por: Jeanfreau, Robert, et al.
Publicado: (2018)

2723. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Adolescents 10–17 Years of Age
por: Peterson, James, et al.
Publicado: (2019)

2719. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Adults 18–55 Years of Age
por: Peterson, James, et al.
Publicado: (2019)

Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy
por: Shirai, Shimpei, et al.
Publicado: (2018)

Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season
por: Jagielska, Anna M., et al.
Publicado: (2021)

SAT-LB65 A Rare Existence
por: Bedia, Jiselle Aimee Yaplito, et al.
Publicado: (2020)

Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022–2023 Winter Season
por: Moss, Stephen, et al.
Publicado: (2023)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

Tissue distribution of a plasmid DNA encoding Hsp65 gene is dependent on the dose administered through intramuscular delivery
por: Coelho-Castelo, AAM, et al.
Publicado: (2006)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

Enhanced Immunogenicity of Adjuvanted Microparticulate HPV16 Vaccines Administered via the Transdermal Route
por: Vo, Trinh Phuong, et al.
Publicado: (2022)

Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study
por: Izikson, Ruvim, et al.
Publicado: (2022)

Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine When Co-Administered with Tetanus-Reduced Diphtheria-Acellular Pertussis and Quadrivalent Meningococcal Conjugate Vaccines in Healthy Adolescents: Results from a Randomized, Observer-Blind, Controlled Trial
por: Miao, Yan, et al.
Publicado: (2019)

MON-LB65 Lithium: The Culprit of Multiple Endocrinopathies
por: Yau, Alice, et al.
Publicado: (2020)

Sedative effects of intramuscular alfaxalone administered to cats
por: TAMURA, Jun, et al.
Publicado: (2015)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

2139. Immunogenicity, reactogenicity and safety of a Respiratory Syncytial Virus prefusion F (RSVPreF3) candidate vaccine co-administered with the seasonal quadrivalent influenza vaccine in older adults
por: Chandler, Reynaldo, et al.
Publicado: (2022)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

2724. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Healthy Meningococcal Vaccine-Naïve Children (2–9 Years)
por: Simon, Michael W, et al.
Publicado: (2019)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study
por: Dhingra, M. S., et al.
Publicado: (2021)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial
por: Dunning, Andrew J., et al.
Publicado: (2016)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children
por: Langley, Joanne M., et al.
Publicado: (2013)

Assessment of Immunogenicity of Adjuvanted Quadrivalent Inactivated Influenza Vaccine in Healthy People and Patients With Common Variable Immune Deficiency
por: Kostinova, Aristitsa Mikhailovna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k3salshto93si6grcja7ej2d57